Aarti Surfactants Ltd Q2 FY26: The Suds Are Bubbling, But The Foam Is Thin — Revenue Up 18.8%, PAT Up 279%, Yet Margins Slipping Like Soap In A Shower

1. At a Glance

Picture this: a ₹363 crore market cap company born out of Aarti Industries’ home and personal care DNA, now trying to find its own identity in a cutthroat surfactant world. Aarti Surfactants Ltd (ASL) just scrubbed in its Q2 FY26 results — and while the top line sparkles with an 18.8% YoY rise to ₹179 crore, the bottom line gleams with a 279% jump in PAT to ₹1.56 crore. Sounds fancy, right? Well, hold the applause. The operating margin slipped to 5.21%, reminding us that volatility in palm oil prices and raw material duties can wash away profits faster than a detergent ad washes stains.

At ₹429 per share, ASL trades at 24.2x earnings — cheaper than Pidilite’s PE bubble bath but pricier than the average midcap soap maker who’s still drying its towel. ROE at 5.14% and ROCE at 8.5% scream: “We’re working hard, but not sweating enough.” The stock has lost 33.5% over the past year, because investors perhaps expected more foam for the fragrance. Still, with sales growth of 28.5% and profit growth of 18.4%, it’s a smallcap trying to lather up credibility — just not yet smelling of success.

2. Introduction

Aarti Surfactants is the youngest offspring of the Aarti family, demerged in 2018 to specialize in surfactants — the real chemical heroes behind your shampoo’s silky promise and your detergent’s fake mountain freshness. It’s like the behind-the-scenes crew in every household product commercial — the ones who make bubbles, not headlines.

The company sells to FMCG royalty like HUL, P&G, and Dabur — meaning its surfactants probably bathe half of India every morning. But here’s the twist: raw material volatility, particularly palm oil derivatives like Lauryl Alcohol, is a recurring villain in its story. The imposition of countervailing duties (CVD) on imported raw materials added a soapy layer of cost pressure.

Despite this, Aarti Surfactants has managed to maintain a modest rhythm — sales rising steadily, profits yo-yoing, and margins slipping every few quarters. Its FY25 revenue stood at ₹659 crore, up from ₹590 crore in FY24, but PAT shrank to ₹15 crore. The dream? Expand capacities at Pithampur and Silvassa with ₹85 crore capex over two years. The risk? Taking ₹60 crore of debt for it when your operating profit is barely ₹50 crore TTM.

Still, there’s something oddly respectable about a smallcap surviving in an industry dominated by chemical titans and oil volatility. Think of it as a plucky sidekick in a superhero movie — a little greasy, slightly broke, but still loyal to the mission.

3. Business Model – WTF Do They Even Do?

In simple desi English — Aarti Surfactants makes chemicals that make other chemicals look good. Their surfactants are what give your shampoo foam, your detergent sparkle, and your lotion that smooth feel. The company’s business can be sliced into three broad areas:

• Primary Surfactants: The workhorses that go into home and personal care — soaps, shampoos, body washes.
• Mild Surfactants: For sensitive skins and baby products (basically, where “no tears formula” meets “low margin reality”).
• Blends: Customized formulations designed per client — or as Aarti calls it, “bespoke bubbles.”

The beauty of the model? Sticky customers. The danger? Price wars and volatile raw materials. ASL supplies to FMCG giants, meaning quality must be spotless, but bargaining power often isn’t. Its raw materials — fatty alcohols, acids, and alpha olefins — are tightly linked to palm oil and petrochemical prices. Any spike there hits gross margins directly.

ASL exports to 30+ countries, but 80% of its sales still come from India. Think of it as the chemical equivalent of a small-town player trying to impress global uncles in a business suit. It’s scaling, but not at the pace one would expect from the Aarti legacy.

4. Financials Overview

Let’s jump into the Q2 FY26 numbers — the latest quarterly report that brought both cheer and caution.

Annualised EPS: 1.84 × 4 = ₹7.36, implying a P/E of around 58x on annualized Q2 numbers (vs current 24x trailing), which